v3.26.1
Earnings/(Loss) Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
EPS/(LPS) Numerator        
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders $ (256) $ 2,885 $ 2,444 $ 5,852
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders (256) 2,885 2,444 5,852
Discontinued operations––net of tax 8 25 (5) 25
Net income/(loss) attributable to Pfizer Inc. common shareholders (248) 2,910 2,440 5,877
Net income/(loss) attributable to Pfizer Inc. common shareholders $ (248) $ 2,910 $ 2,440 $ 5,877
EPS/(LPS) Denominator        
Weighted-average number of common shares outstanding––Basic (in shares) 5,699 5,685 5,695 5,680
Common-share equivalents (in shares) [1] 0 21 38 28
Weighted-average number of common shares outstanding––Diluted (in shares) 5,699 5,706 5,733 5,708
Anti-dilutive common stock equivalents (in shares) [2] 45 8 11 12
[1] For the three months ended June 28, 2026, due to the net loss attributable to Pfizer Inc. common shareholders, weighted average common-share equivalents of 35 million shares were not included in the computation of diluted LPS because their inclusion would have had an anti-dilutive effect.
[2] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS/(LPS) for those periods because their inclusion would have had an anti-dilutive effect.